Kelly Weitzel

May 10, 2024 | bioprocessintl.com | Gareth Macdonald |Cheryl Scott |Peter Alexander |Kelly Weitzel

STOCK.ADOBE.COMAntibody–drug conjugates (ADCs) are straightforward as a concept. When a cytotoxic small-molecule drug is attached to an antibody raised against a specific molecular receptor, it theoretically creates a highly targeted and effective therapy. And the ability to target cells precisely has obvious applications for indications such as cancer. However, in practice, developing and manufacturing ADCs has proven difficult, said Janice M.

Sep 19, 2023 | bioprocessintl.com | Peter Alexander |Kelly Weitzel |Angela Linderholm |William E. Haskins

The pharmaceutical industry has come a long way since 1907, when Paul Ehrlich coined the term “magic bullet” for treatments that could target disease-causing cells while sparing normal, healthy cells (1, 2). Researchers began investigating targeted cytotoxins as therapeutic bioconjugates in the late 1980s. Groups led by Ellen Vitetta at the University of Texas Southwestern Medical Center (3), Ira Pastan at the US National Institutes of Health (4), and John R.